Cooley advised Oyster Point Pharma on the deal, while Cravath represented Viatris. Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, announced its definitive agreement to be acquired...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
